NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,044.20 | 62.10 | -0.68% |
| CAC 40 | 7,872.02 | 41.91 | 0.54% |
| DAX 40 | 23,611.33 | 84.28 | 0.36% |
| Dow JONES (US) | 46,292.78 | 88.76 | -0.19% |
| FTSE 100 | 9,223.32 | 3.36 | -0.04% |
| HKSE | 26,386.63 | 227.51 | 0.87% |
| NASDAQ | 22,573.47 | 215.50 | -0.95% |
| Nikkei 225 | 45,528.39 | 34.73 | 0.08% |
| NZX 50 Index | 13,181.31 | 44.77 | 0.34% |
| S&P 500 | 6,656.92 | 36.83 | -0.55% |
| S&P/ASX 200 | 8,751.00 | 64.00 | -0.73% |
| SSE Composite Index | 3,841.01 | 19.18 | 0.50% |